ReNeuron Group PLC - Bridgend, Wales-based stem cell and exosomes technology company - Negotiates a supplemental terms agreement with Shanghai Fosun Pharmaceutical Group Co Ltd. Company says the agreement has the potential to generate revenue of up to £6 million.

The agreement relates to ReNeuron’s stroke disability programme. ReNeuron expects to receive around £1 million over the next 24 months for the supply of CTX cell bank vials and services, with a further £5 million receivable over the medium to long term for continued provision of these vials.

Current stock price: 27.90 pence, up 0.5% in London on Friday

12-month change: down 74%

Copyright 2022 Alliance News Limited. All Rights Reserved.